Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go

Future Oncol. 2019 Jul;15(19):2199-2202. doi: 10.2217/fon-2019-0217. Epub 2019 Jun 19.

Thomas Gevaert^{1

2

3}, Alessia Cimadamore⁴, Markus Eckstein⁵, Marina Scarpelli⁴, Antonio Lopez-Beltran⁶, Liang Cheng⁷, Rodolfo Montironi⁴

¹ Department of Urology, UZ Leuven, Leuven, Belgium.
² Organ Systems, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
³ Department of Pathology, AZ Klina, Brasschaat, Belgium.
⁴ Section of Pathological Anatomy, Marche Polytechnic University, School of Medicine, United Hospitals, Ancona, Italy.
⁵ Department of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
⁶ Department of Surgery, Cordoba University Medical School, Cordoba, Spain.
⁷ Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

No abstract available

Keywords: PD-L1; atezolizumab; basal-type; genitourinary tumors; immunotherapy; luminal-type; lymphocytes; microbiome; urothelial carcinoma.

Publication types